^
    12ms
    Establishment and characterization of amitrole-induced mouse thyroid adenomatous nodule-derived cell lines. (PubMed, Thyroid)
    Signal transduction and cell proliferation were evaluated after treatment with insulin-like growth factor-I (IGF-I) and the selective IGF-I receptor (IGF-IR) inhibitor NVP-ADW742...They lacked tumorigenicity and prominent gene mutations involved in thyroid cancer development, while missense mutations were found in some tumor suppressors as revealed by WGS. The CAT458s and 459 provide a new tool to further clarify the process of thyroid multi-step carcinogenesis and differentiation.
    Preclinical • Journal
    |
    BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • TERT (Telomerase Reverse Transcriptase) • IGF1 (Insulin-like growth factor 1) • TGFB1 (Transforming Growth Factor Beta 1) • POLK (DNA Polymerase Kappa)
    |
    TP53 mutation • NKX2-1 expression
    |
    NVP-ADW742
    over3years
    IGF-1R depletion sensitizes colon cancer cell lines to radiotherapy. (PubMed, Cancer Biomark)
    Our findings demonstrate that depletion of IGF-1R lead to an increase in radiosensitivity in CRC.
    Preclinical • Journal
    |
    HRD (Homologous Recombination Deficiency) • RAD51 (RAD51 Homolog A) • TP53BP1 (Tumor Protein P53 Binding Protein 1)
    |
    NVP-ADW742
    4years
    The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells. (PubMed, Cancer Lett)
    In addition, FLNA knockdown potentiated antiproliferative effects of IGF1R/IR inhibitor Linsitinib and IGF1R inhibitor NVP-ADW742 in H295R. Finally, Western blot showed lower FLNA expression in ACCs (n = 10) than in ACAs (n = 10) and an inverse correlation of FLNA/IGF1R ratio with ERK phosphorylation in ACCs only. In conclusion, we demonstrated that low FLNA levels enhance both IGF2 proliferative effects and IGF1R/IR inhibitors efficacy in ACC cells, suggesting FLNA as a new factor influencing tumor clinical behavior and the response to the therapy with IGF1R/IR-targeted drugs.
    Clinical • Journal
    |
    IGF2 (Insulin-like growth factor 2)
    |
    IGF2 overexpression
    |
    linsitinib (ASP7487) • NVP-ADW742